Updated:
MindMaze
Tej Tadi's Lausanne-based neurotechnology platform, founded 2012, commercializes FDA-cleared brain-computer interfaces and VR middleware.
MindMaze
Neuroscientist Tej Tadi established MindMaze in Lausanne in 2012, spinning out more than a decade of academic research in neural engineering and virtual reality. The firm originated within the Swiss Federal Institute of Technology ecosystem and attracted early backing from a consortium of family offices and sovereign-linked investors, including a notable 2017 round led by Hinduja Group. MindMaze operates across two distinct business lines. Its healthcare division markets the MindMotion platform, which received FDA clearance in 2017 for upper-limb neurorehabilitation after stroke and traumatic brain injury. The M-Gen division commercializes licensable neurogaming middleware — motion-capture and facial-expression tracking engines embedded in third-party AR/VR titles. Deployment spans the US, Switzerland, the United Kingdom, and India through hospital-system contracts and original-equipment-manufacturer partnerships with companies such as Penumbra. February 2022: MindMaze merged its digital neurotherapeutics division with SPAC objective, though the deal was later terminated amid broader market repricing of pre-revenue biotech vehicles (per Fierce Biotech, 2022). The firm subsequently restructured around its medical-device recurring revenue stream and the M-Gen licensing pipeline. Known co-development partners include Mount Sinai Health System and the University of California, San Francisco. MindMaze sits structurally between a regulated medical-device company and a technology licensor — a posture that separates it from pure-play digital-health startups. Its intellectual-property portfolio contains over 50 granted patents covering real-time neural decoding, haptic feedback loops, and cross-platform avatar-control systems, creating a dual moat in clinical reimbursement pathways and entertainment royalty economics.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Lausanne
Corporate office
Lausanne, Switzerland
Principals
Tej Tadi
CEO and Founder
Sector focus
Frequently asked questions
Is MindMaze a medical-device company, a software firm, or an investment vehicle?
MindMaze operates as a hybrid — a regulated medical-device manufacturer subject to FDA and CE-mark requirements on the healthcare side, and a technology licensing business on the content side. It has raised VC-style growth equity rather than operating as a controlled family balance sheet. No single family office owns a majority stake, though the Hinduja Group led a significant round in 2017.
What does FDA clearance for the MindMotion platform actually cover?
The 2017 FDA 510(k) clearance covers upper-limb motor rehabilitation for adult stroke and traumatic-brain-injury patients in clinical settings. It does not cover at-home use or lower-limb indications. The system uses motion-capture cameras and virtual-reality exercises to deliver repetitive-task training, with outcomes data collected through integrated patient-facing dashboards.
Who competes directly with MindMaze in neurorehabilitation?
Direct competitors in robotic and VR-assisted neurorehabilitation include Hocoma (DIH International), Ekso Bionics, and Tyromotion. MindMaze differentiates through its non-robotic motion-capture approach and the cross-pollination of content assets between its clinical and entertainment divisions — a structure no competitor replicates.
How does MindMaze generate revenue from its content division?
The M-Gen division licenses a middleware engine that performs real-time face-tracking, emotion recognition, and body-motion capture. Revenue comes through per-seat licensing agreements with game studios, AR/VR headset manufacturers, and enterprise training platforms. Exact contract values are not publicly disclosed.
What is the relationship between MindMaze and the Hinduja Group?
The Hinduja Group, a multinational conglomerate controlled by the Hinduja family, led a funding round in 2017 of undisclosed size. The relationship has not resulted in a board takeover or majority control; the firm remains operationally led by founder Tej Tadi from Lausanne.
Has MindMaze been through a SPAC process or considered going public?
In February 2022, MindMaze announced a merger of its digital neurotherapeutics division with a SPAC vehicle. The transaction was terminated later that year amid deteriorating market conditions for pre-revenue biotech companies. The firm has not announced new public-listing plans since.
Which geographical markets generate the majority of MindMaze's clinical revenue?
The US market accounts for the largest share of hospital-system installations, driven by the FDA-cleared indication and rehabilitation-facility reimbursement codes. European revenue is concentrated in Switzerland, Germany, and the UK through NHS and university-hospital procurement. India serves as a development hub and an emerging clinical-distribution market via the Hinduja Group's hospital network.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: